Omnicell (NASDAQ:OMCL) Releases FY 2024 Earnings Guidance

Omnicell (NASDAQ:OMCL) updated its FY 2024 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of 1.200-1.500 for the period, compared to the consensus estimate of 1.110. The company issued revenue guidance of $1.1 billion-$1.1 billion, compared to the consensus revenue estimate of $1.1 billion. Omnicell also updated its FY24 guidance to $1.20-1.50 EPS.

Wall Street Analyst Weigh In

Several brokerages have weighed in on OMCL. StockNews.com cut Omnicell from a buy rating to a hold rating in a report on Tuesday, July 16th. Benchmark reaffirmed a buy rating and issued a $38.00 price target on shares of Omnicell in a research note on Monday, July 15th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of Hold and an average target price of $42.20.

Omnicell Trading Up 29.2 %

Shares of OMCL stock traded up $8.52 on Thursday, reaching $37.73. The company had a trading volume of 1,159,917 shares, compared to its average volume of 517,429. The company has a current ratio of 2.38, a quick ratio of 2.13 and a debt-to-equity ratio of 0.48. The company has a 50-day moving average of $28.56 and a 200-day moving average of $29.00. Omnicell has a 12 month low of $25.12 and a 12 month high of $66.65. The stock has a market cap of $1.73 billion, a PE ratio of -77.85, a PEG ratio of 82.28 and a beta of 0.80.

Omnicell (NASDAQ:OMCL) last released its quarterly earnings results on Thursday, May 2nd. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.31) by $0.17. Omnicell had a negative net margin of 1.91% and a positive return on equity of 2.41%. The company had revenue of $246.15 million during the quarter, compared to analysts’ expectations of $235.70 million. On average, equities analysts forecast that Omnicell will post 0.25 earnings per share for the current year.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.